In vivo comparison of macrocyclic and acyclic ligands for radiolabeling of monoclonal antibodies with 177Lu for radioimmunotherapeutic applications

Diane E. Milenic, Kayhan Garmestani, Lara L. Chappell, Ekaterina Dadachova, Alexander Yordanov, Dangshe Ma, Jeffrey Schlom, Martin W. Brechbiel

Research output: Contribution to journalArticle

96 Citations (Scopus)

Abstract

The studies reported herein present the first in vitro and in vivo comparison of radioimmunoconjugates (RIC) radiolabeled with 177Lu using the acyclic CHX-A″-DTPA ligand and the macrocyclic ligands, C-DOTA and PA-DOTA. The in vivo studies include pharmacokinetics and biodistribution of the formed 177Lu-labeled immunoconjugates in a tumor bearing murine model with engineered monoclonal antibody HuCC49ΔCH2. The in vitro analysis indicated that the CHX-A″ RIC was superior with respect to immunoreactivity, radiolabeling with 177Lu, and specific activity. The in vivo pharmacokinetic data by itself indicated that the Lu(III)-PA-DOTA complex may not be as stable as Lu(III) complexes with CHX-A″ or C-DOTA. All three RICs demonstrated tumor targeting of human colon carcinoma xenografts in athymic mice. In these biodistribution studies, there appears to be no overall pattern or trend of one RIC over the other two. Based on these in vitro and in vivo studies, the CHX-A″ DTPA ligand should be considered a suitable bifunctional chelate for the radiolabeling of monoclonal antibodies with 177Lu for radioimmunotherapy applications.

Original languageEnglish (US)
Pages (from-to)431-442
Number of pages12
JournalNuclear Medicine and Biology
Volume29
Issue number4
DOIs
StatePublished - 2002
Externally publishedYes

Fingerprint

Immunoconjugates
Monoclonal Antibodies
Ligands
Pharmacokinetics
Radioimmunotherapy
Heterografts
Nude Mice
Neoplasms
Colon
Carcinoma
N-(2-amino-3-(4-isothiocyanatophenyl)propyl)cyclohexane-1,2-diamine-N,N',N',N'',N''-pentaacetic acid
In Vitro Techniques
4-aminophenylethyl-1,4,7,10-tetraazacyclodecane-N,N',N'',N'''-tetraacetic acid

Keywords

  • CHX-A″
  • DOTA
  • Lu-177
  • PA-DOTA
  • Radioimmunotherapy

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Medicine
  • Radiology Nuclear Medicine and imaging

Cite this

In vivo comparison of macrocyclic and acyclic ligands for radiolabeling of monoclonal antibodies with 177Lu for radioimmunotherapeutic applications. / Milenic, Diane E.; Garmestani, Kayhan; Chappell, Lara L.; Dadachova, Ekaterina; Yordanov, Alexander; Ma, Dangshe; Schlom, Jeffrey; Brechbiel, Martin W.

In: Nuclear Medicine and Biology, Vol. 29, No. 4, 2002, p. 431-442.

Research output: Contribution to journalArticle

Milenic, Diane E. ; Garmestani, Kayhan ; Chappell, Lara L. ; Dadachova, Ekaterina ; Yordanov, Alexander ; Ma, Dangshe ; Schlom, Jeffrey ; Brechbiel, Martin W. / In vivo comparison of macrocyclic and acyclic ligands for radiolabeling of monoclonal antibodies with 177Lu for radioimmunotherapeutic applications. In: Nuclear Medicine and Biology. 2002 ; Vol. 29, No. 4. pp. 431-442.
@article{d70702e27ec74ad482f85db15a3709c3,
title = "In vivo comparison of macrocyclic and acyclic ligands for radiolabeling of monoclonal antibodies with 177Lu for radioimmunotherapeutic applications",
abstract = "The studies reported herein present the first in vitro and in vivo comparison of radioimmunoconjugates (RIC) radiolabeled with 177Lu using the acyclic CHX-A″-DTPA ligand and the macrocyclic ligands, C-DOTA and PA-DOTA. The in vivo studies include pharmacokinetics and biodistribution of the formed 177Lu-labeled immunoconjugates in a tumor bearing murine model with engineered monoclonal antibody HuCC49ΔCH2. The in vitro analysis indicated that the CHX-A″ RIC was superior with respect to immunoreactivity, radiolabeling with 177Lu, and specific activity. The in vivo pharmacokinetic data by itself indicated that the Lu(III)-PA-DOTA complex may not be as stable as Lu(III) complexes with CHX-A″ or C-DOTA. All three RICs demonstrated tumor targeting of human colon carcinoma xenografts in athymic mice. In these biodistribution studies, there appears to be no overall pattern or trend of one RIC over the other two. Based on these in vitro and in vivo studies, the CHX-A″ DTPA ligand should be considered a suitable bifunctional chelate for the radiolabeling of monoclonal antibodies with 177Lu for radioimmunotherapy applications.",
keywords = "CHX-A″, DOTA, Lu-177, PA-DOTA, Radioimmunotherapy",
author = "Milenic, {Diane E.} and Kayhan Garmestani and Chappell, {Lara L.} and Ekaterina Dadachova and Alexander Yordanov and Dangshe Ma and Jeffrey Schlom and Brechbiel, {Martin W.}",
year = "2002",
doi = "10.1016/S0969-8051(02)00294-9",
language = "English (US)",
volume = "29",
pages = "431--442",
journal = "Nuclear Medicine and Biology",
issn = "0969-8051",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - In vivo comparison of macrocyclic and acyclic ligands for radiolabeling of monoclonal antibodies with 177Lu for radioimmunotherapeutic applications

AU - Milenic, Diane E.

AU - Garmestani, Kayhan

AU - Chappell, Lara L.

AU - Dadachova, Ekaterina

AU - Yordanov, Alexander

AU - Ma, Dangshe

AU - Schlom, Jeffrey

AU - Brechbiel, Martin W.

PY - 2002

Y1 - 2002

N2 - The studies reported herein present the first in vitro and in vivo comparison of radioimmunoconjugates (RIC) radiolabeled with 177Lu using the acyclic CHX-A″-DTPA ligand and the macrocyclic ligands, C-DOTA and PA-DOTA. The in vivo studies include pharmacokinetics and biodistribution of the formed 177Lu-labeled immunoconjugates in a tumor bearing murine model with engineered monoclonal antibody HuCC49ΔCH2. The in vitro analysis indicated that the CHX-A″ RIC was superior with respect to immunoreactivity, radiolabeling with 177Lu, and specific activity. The in vivo pharmacokinetic data by itself indicated that the Lu(III)-PA-DOTA complex may not be as stable as Lu(III) complexes with CHX-A″ or C-DOTA. All three RICs demonstrated tumor targeting of human colon carcinoma xenografts in athymic mice. In these biodistribution studies, there appears to be no overall pattern or trend of one RIC over the other two. Based on these in vitro and in vivo studies, the CHX-A″ DTPA ligand should be considered a suitable bifunctional chelate for the radiolabeling of monoclonal antibodies with 177Lu for radioimmunotherapy applications.

AB - The studies reported herein present the first in vitro and in vivo comparison of radioimmunoconjugates (RIC) radiolabeled with 177Lu using the acyclic CHX-A″-DTPA ligand and the macrocyclic ligands, C-DOTA and PA-DOTA. The in vivo studies include pharmacokinetics and biodistribution of the formed 177Lu-labeled immunoconjugates in a tumor bearing murine model with engineered monoclonal antibody HuCC49ΔCH2. The in vitro analysis indicated that the CHX-A″ RIC was superior with respect to immunoreactivity, radiolabeling with 177Lu, and specific activity. The in vivo pharmacokinetic data by itself indicated that the Lu(III)-PA-DOTA complex may not be as stable as Lu(III) complexes with CHX-A″ or C-DOTA. All three RICs demonstrated tumor targeting of human colon carcinoma xenografts in athymic mice. In these biodistribution studies, there appears to be no overall pattern or trend of one RIC over the other two. Based on these in vitro and in vivo studies, the CHX-A″ DTPA ligand should be considered a suitable bifunctional chelate for the radiolabeling of monoclonal antibodies with 177Lu for radioimmunotherapy applications.

KW - CHX-A″

KW - DOTA

KW - Lu-177

KW - PA-DOTA

KW - Radioimmunotherapy

UR - http://www.scopus.com/inward/record.url?scp=0035988205&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035988205&partnerID=8YFLogxK

U2 - 10.1016/S0969-8051(02)00294-9

DO - 10.1016/S0969-8051(02)00294-9

M3 - Article

C2 - 12031878

AN - SCOPUS:0035988205

VL - 29

SP - 431

EP - 442

JO - Nuclear Medicine and Biology

JF - Nuclear Medicine and Biology

SN - 0969-8051

IS - 4

ER -